Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
June 30, 2021 22:44 ET | Source: Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals, Inc. Charlottesville, Virginia, UNITED STATES
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimer’s disease, today announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to Acumen, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $160 million. All of the shares of common stock are being offered by Acumen. In addition, Acumen has granted the underw
EverCommerce Announces Pricing of Initial Public Offering
July 01, 2021 00:04 ET | Source: EverCommerce Inc. EverCommerce Inc. Denver, Colorado, UNITED STATES
DENVER, July 01, 2021 (GLOBE NEWSWIRE) EverCommerce Inc. (“EverCommerce”), a leading service commerce platform, announced today the pricing of its initial public offering of 19,117,648 shares of its common stock at a public offering price of $17.00 per share. The shares are expected to begin trading on the NASDAQ Global Select Market on July 1, 2021, under the ticker symbol “EVCM.” The initial public offering is expected to close on July 6, 2021, subject to customary closing conditions.
In addition, the underwriters have been granted a 30-day option to purchase up to an additional 2,867,647 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
MIL-OSI: EverCommerce Announces Pricing of Initial Public Offering foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.
Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimer’s disease, today announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to Acumen, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $160 million. All of the shares of common stock are being offered by Acumen. In addition, Acumen has granted the underwriters a 30-day option to purchase up to an additional 1,499,999 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
Integral Ad Science Announces Pricing of Initial Public Offering
News provided by
Share this article
Share this article
NEW YORK, June 29, 2021 /PRNewswire/ Integral Ad Science ( IAS ), a global leader in digital media quality, today announced the pricing of its initial public offering of 15,000,000 shares of common stock at a price of $18 per share. The underwriters have a 30-day option to purchase up to an additional 2,250,000 shares of common stock from IAS. The shares of common stock are expected to begin trading on the Nasdaq Stock Market under the ticker symbol IAS on June 30, 2021. The offering is expected to close on July 2, 2021, subject to the satisfaction of customary closing conditions.